Kraj: Stany Zjednoczone
Język: angielski
Źródło: NLM (National Library of Medicine)
CLONAZEPAM (UNII: 5PE9FDE8GB) (CLONAZEPAM - UNII:5PE9FDE8GB)
Direct_Rx
ORAL
PRESCRIPTION DRUG
Seizure Disorders: Clonazepam is useful alone or as an adjunct in the treatment of the Lennox-Gastaut syndrome (petit mal variant), akinetic, and myoclonic seizures. In patients with absence seizures (petit mal) who have failed to respond to succinimides, clonazepam may be useful. Some loss of effect may occur during the course of clonazepam treatment (see PRECAUTIONS: LOSS OF EFFECT). Panic Disorder: Clonazepam is indicated for the treatment of panic disorder, with or without agoraphobia, as defined in DSM-V. Panic disorder is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and/or a significant change in behavior related to the attacks. The efficacy of clonazepam was established in two 6- to 9-week trials in panic disorder patients whose diagnoses corresponded to the DSM-IIIR category of panic disorder (see CLINICAL PHARMACOLOGY: CLINICAL TRIALS). Panic disorder (DSM-V) is characte
Clonazepam Tablets, USP are available as: 0.5 mg: light yellow, flat-faced beveled edge tablets, scored, debossed "2530" on one side and debossed "V" on the reverse side, available as follows: • Bottles of 100: NDC 43547-406-10 • Bottles of 500: NDC 43547-406-50 • Bottles of 1000: NDC 43547-406-11 1 mg: light blue, flat-faced beveled edge tablets, unscored, debossed "2531" on one side and debossed "V" on the reverse side, available as follows: • Bottles of 30: NDC 72189-475-30 • Bottles of 60: NDC 72189-475-60 2 mg: white, flat-faced beveled edge tablets, unscored, debossed "2532" on one side and debossed "V" on the reverse side, available as follows: • Bottles of 100: NDC 43547-408-10 • Bottles of 500: NDC 43547-408-50
Abbreviated New Drug Application
CLONAZEPAM- CLONAZEPAM TABLET Direct_Rx ---------- Dispense with Medication Guide available at: WWW.SOLCOHEALTHCARE.COM/MEDGUIDE/CLONAZEPAM-TABLETS.PDF Clonazepam Tablets for oral use What is the most important information I should know about clonazepam tablets? • Clonazepam tablets are benzodiazepine medicine. Taking benzodiazepines with opioid medicines, alcohol, or other central nervous system (CNS) depressants (including street drugs) can cause severe drowsiness, breathing problems (respiratory depression), coma, and death. Get emergency help right away if any of the following happens: o shallow or slowed breathing o breathing stops (which may lead to the heart stopping) o excessive sleepiness (sedation) Do not drive or operate heavy machinery until you know how taking clonazepamtablets and opioids affects you. • Risk of abuse, misuse, and addiction. There is a risk of abuse, misuse, and addiction with benzodiazepines, including clonazepam tablets, which can lead to overdose and serious side effects including coma and death. o Serious side effects including coma and death have happened in people who have abused or misused benzodiazepines, including clonazepam tablets. These serious side effects may also include delirium, paranoia, suicidal thoughts or actions, seizures, and difficulty breathing. Call your healthcare provider or go to the nearest hospital emergency room right away if you get any of these serious side effects. o You can develop an addiction even if you take clonazepam tablets as prescribed by your healthcare provider. o Take clonazepam tablets exactly as your healthcare provider prescribed. o Do not share your clonazepamtablets with other people. o Keep clonazepam tablets in a safe place and away from children. • Physical dependence and withdrawal reactions. Clonazepam tablets can cause physical dependence and withdrawal reactions. o Do not suddenly stop taking clonazepam tablets. Stopping clonazepam tablets suddenly can cause serious and life-threatening side effects, including, unusual Przeczytaj cały dokument
CLONAZEPAM- CLONAZEPAM TABLET DIRECT_RX ---------- CLONAZEPAM WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; AND DEPENDENCE AND WITHDRAWAL REACTIONS • Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation (see WARNINGS and PRECAUTIONS). • The use of benzodiazepines, including clonazepam, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. Before prescribing clonazepam and throughout treatment, assess each patient’s risk for abuse, misuse, and addiction (see WARNINGS). • The continued use of benzodiazepines, including clonazepam, may lead to clinically significant physical dependence. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose. Abrupt discontinuation or rapid dosage reduction of clonazepam after continued use may precipitate acute withdrawal reactions, which can be life-threatening. To reduce the risk of withdrawal reactions, use a gradual taper to discontinue clonazepam or reduce the dosage (see DOSAGE AND ADMINISTRATION and WARNINGS). Clonazepam Tablets USP, a benzodiazepine, is available as scored tablets containing 0.5 mg of clonazepam and unscored tablets containing 1 mg or 2 mg of clonazepam. Each tablet also contains colloidal silicon dioxide, croscarmellose sodium, lactose monohydrate, magnesium stearate and microcrystalline cellulose, with the following colorants: 0.5 mg – D&C Yellow #10 aluminum lake; 1 mg – FD&C Blue #1 aluminum lake. Chemically, clonazep Przeczytaj cały dokument